--- title: "A Chinese cochlear implant has reached 30,000 users — and cleared the auditory brainstem" date: 2026-11-09 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-brain-nurotron-cochlear-abi language: en --- # A Chinese cochlear implant has reached 30,000 users — and cleared the auditory brainstem > Hangzhou's Nurotron has fitted about 30,000 cochlear implants and won the first Chinese approval of an auditory brainstem implant, ending a long foreign monopoly on hearing restoration. A mother outside Hangzhou presses a small processor behind her daughter's ear and hears the child laugh for the first time. The device that made it possible was not built in Austria or Australia. It was built a few kilometers away, by a company that spent nearly two decades learning to rebuild a sense most people never think about. For a long time, restoring hearing through electronics was a club with only three members. Until the late 2000s, only the United States, Australia and Austria could make a cochlear implant — the device that bypasses dead hair cells in the inner ear and stimulates the auditory nerve directly. China became the fourth country to do it independently, and the company behind that milestone is Nurotron (诺尔康), based in Hangzhou's Future Sci-Tech City. ## Key takeaways - Nurotron has fitted its cochlear implants in about 30,000 people in China and abroad; in a 2025 announcement the company put its domestic market share at about 20 percent. - The company's auditory brainstem implant (ABI) became the first domestically developed ABI to win Chinese regulatory approval, serving patients whose cochleas cannot be implanted at all. - Nurotron has taken part in drafting four national brain–computer interface (脑机接口) standards, extending its reach from hearing into the broader neurotech rulebook. ## Why a cochlear implant is a neural interface A cochlear implant is, at its core, a neural interface: it converts sound into electrical patterns and feeds them straight into the auditory nerve. Before Nurotron, a Chinese family facing severe hearing loss had few choices — pay foreign manufacturers, or stay silent. Imported devices ran as high as 250,000 yuan per ear. Nurotron's entry pushed that figure down sharply, and the company says imported prices fell to around 150,000 yuan as competition tightened. The engineering was not trivial. Packing a circuit board the size of a dining table into a coin-sized implant that must survive inside a human body for decades took the team about two years on that single problem. Nurotron was founded in 2006 by Li Fangping, a businessman who had made his money in real estate and decided the hearing-loss market was worth disrupting. The company says it has filed more than 160 patents and won China's National Science and Technology Progress Award (second class) twice — in 2015 and again in 2024. ## The harder barrier: the brainstem Some patients cannot use a cochlear implant at all. People born without a working auditory nerve, or those whose cochlear structure was destroyed by tumors or severe malformation, have nothing for a cochlear device to stimulate. For them the target moves from the inner ear to the brainstem itself. That is what an auditory brainstem implant does: it places electrodes directly on the brainstem's hearing nucleus, bypassing the ear and nerve entirely. In October 2026, Nurotron and Shanghai Ninth People's Hospital announced that China's first domestically developed ABI had received National Medical Products Administration (NMPA, 国家药监局) registration approval — filling a domestic blank. The company says the product took about seven years to move from design to approval. ## A state-backed turn In 2025, Hangzhou's state-owned investment platforms took a strategic equity stake in Nurotron, described by the company as worth several hundred million yuan (≈ US$40–70M / HK$330–550M). The move is less about rescuing a struggling firm and more about anchoring a "neuro-electronics" industrial cluster inside Hangzhou's corridor of science parks. Nurotron says it now serves roughly 430 hospitals in China and 530 worldwide, and that its longest-serving implant has been safely inside a person for more than 17 years. ## The bigger play: standards Here is where the story connects to the wider brain–computer interface (脑机接口) race. Nurotron's leadership has said the company took part in drafting four national brain–computer interface standards and is leading or joining seven national and provincial BCI projects plus four provincial key laboratories. The more interesting shift is not any single product but China's move from importing neural implants to helping write the rules those implants must follow. That is a quiet but real change. For two decades Nurotron's value was measured in ears helped. Increasingly its value is also measured in whose specifications the next generation of neural devices will be built to. ## What readers can do now - **If hearing loss touches your family**, ask audiologists about domestically made implants and compare total cost of ownership — processor upgrades and aftercare matter as much as the surgery price. - **Watch the ABI approval's real-world rollout**: a registered device and a widely available one are different things; track how many centers actually offer it. - **Follow the standards, not just the stock**: national BCI standards will shape which products reach clinics, so monitor the drafting bodies, not only company press releases. ## Honest limitations This article relies on Nurotron's own corporate disclosures, its newsroom, and Chinese media coverage; we did not independently audit surgical volumes or market-share figures against hospital procurement records. The "30,000 implants" and "20 percent domestic share" figures are company-reported (the share figure comes from a May 2025 company announcement) and broadly consistent with secondary reporting, but the precise denominators are not public. The seven-year ABI approval timeline and the "first domestic ABI" claim originate from the company and an affiliated hospital announcement; we could not locate a plain-language independent confirmation beyond the NMPA registration itself. The state investment figure is given only as a range ("several hundred million yuan") by the company, so the USD/HKD conversion is necessarily approximate. Long-term reliability beyond 17 years remains a projection from lab data, not observed patient experience. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-nurotron-cochlear-abi Free to quote with attribution and a link to the original.